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Abstract The immune responses elicited in mice by different
forms of the VP3(110^121) B-epitope of the hepatitis A virus
(HAV) were studied. Different forms of incorporation in
liposomes were tested, encapsulation, rather than surface
exposure, being the best antigenic preparation. Three larger
peptides of the VP3 epitope, two of them containing a hepatitis B
virus T-epitope, and a third containing a putative T-epitope of
HAV (VP3(102^121)) were assayed. While this latter T-epitope
induced an enhancement of the response against the VP3 B-
epitope, the artificially coupled T-epitopes failed to induce a
significant increase. The administration of two multiple antigenic
peptide (MAP) constructs, the first containing the VP3(110^121)
and VP1(11^25) HAV sequences and the second only the
VP1(11^25) sequence, also suggested the presence of a T-
epitope, since the response against the VP1 peptide was increased
in the first construct.
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1. Introduction
Hepatitis A virus (HAV) is a hepatotropic virus which is
classi¢ed as genus Hepatovirus within the Picornaviridae fam-
ily [1]. The virion capsid is composed of structural proteins:
VP1, VP2, VP3, and, possibly, VP4 [2]. Although hepatitis A
is not considered a severe disease, it continues to be a source
of mortality in both developed and developing countries [3].
The developed formalin-inactivated HAV vaccines [4,5] rep-
resent a substantial step forward in the control of infections in
developed countries. However, the poor yields of HAV in cell
cultures [6] cause high production costs and pose serious dif-
¢culties to the use of this vaccine in developing areas. As an
alternative, the use of new strategies based on synthetic pep-
tides which can elicit an e⁄cient immune response o¡ers the
advantage of high purity, de¢ned structure and safety [7,8].
However, the use of synthetic peptides as HAV immunogens
presents an important di⁄culty since the major viral neutral-
isation epitopes appear to be discontinuous [9]. Despite this
fact, one sequence exists in the VP1 protein [10,11] and one
sequence in the VP3 protein [12] susceptible to be used as
HAV immunogens. The immunogenicity of the VP1(11^25)
sequence has been described elsewhere [11], and in the present
work we will present the immunogenicity of the VP3(110^121)
sequence. One of the major unsolved problems of the use of
synthetic vaccines is that they usually are poorly immunogenic
and often require vehicles or carriers to evoke an immune
response. In this study, di¡erent delivery systems are tested
in order to enhance the immunogenicity of the VP3 peptide
such as liposomes and synthetic amino acid polymers.
2. Materials and methods
2.1. Cells and viruses
FRhK-4 cell cultures were used to propagate and assay the cyto-
pathogenic HM-175 (courtesy of T. Cromeans, Centres for Disease
Control, Atlanta, GA, USA) strain of HAV [13]. Viral enumerations
were performed by calculating the most probable number of cytopa-
thogenic units per ml (MPNCU/ml) by infecting cell monolayers
grown in 96-well microtitre plates [14]. Sixteen wells were infected
for each dilution, and 20 Wl of inoculum was added to each well.
Data were processed with an MPN computer programme [15].
2.2. Synthetic peptides
Peptides containing the VP3(110^121) (FWRGDLVFDFQV) epi-
tope were synthesised by the continuous-£ow Fmoc-polyamide sol-
id-phase method [16]. Peptides were puri¢ed by semi-preparative
HPLC and the purity achieved was greater than 95%. To enhance
the immunogenicity of the VP3 epitope, this sequence was adminis-
tered in several forms: combined with liposomes, combined with T-
epitopes and liposomes, and as multiple antigenic peptide (MAP)
constructs. Three liposome incorporation approaches were employed:
entrapment into liposomes (liposomes-VP3), entrapment into lipo-
somes after derivatisation with palmitic acid (liposomes-palmitoyl-
VP3), and covalent binding to liposomes (liposomes-covalent-VP3).
Three T-epitope constructs were also assayed: a longer peptide incor-
porating at the amino termini a 15-mer peptide (HBsAg) derived from
an anti-idiotype sequence of the hepatitis B virus surface antigen that
contains B- and T-epitopes (Anti-id 2F10) [17] and entrapped into
liposomes (Anti-id 2F10-VP3), a second construct incorporating the
Anti-id 2F10 at the carboxy termini and entrapped into liposomes
(VP3-Anti-id 2F10), and ¢nally a longer VP3 peptide entrapped into
liposomes VP3(102^121). This larger sequence of the natural HAV
VP3 protein is predicted to contain a T-epitope following the amphi-
pathic helical pro¢le of the protein and in foot-and-mouth disease
virus (FMDV) contains a T-epitope [18]. MAP constructs employed
were MAP4-VP3, incorporating 4 molecules of VP3(110^121) and
MAP2ÿ2-VP3-VP1, incorporating 2 molecules of each VP3(110^121)
and VP1(11^25). A MAP4-VP1 was also administered to perform
comparative studies with the VP3/VP1 construct. All these forms
are summarised in Figs. 1^3.
2.3. Antibody production
Six-week old female Swiss mice were used to obtain ascitic anti-
bodies, after immunisation with the di¡erent synthetic peptides em-
ploying Freund’s complete adjuvant (FCA) as enhancer [11]. The
peptide preparations were administered diluted 1:10 in FCA, in ¢ve
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doses of 50 Wg of peptide each, at weeks 0, 2, 3, 4 and 5. Ascites
generated by inoculation of PBS diluted 1:10 in FCA were used as
negative controls, while ascites generated by inoculation of 30 ng of
intact HAV particles were used as positive controls.
2.4. Peptide recognition
Peptide recognition by anti-peptide antibodies was assayed by a
direct enzyme-linked immunosorbent assay (ELISA), in which plates
were coated with the VP3(110^121) peptide or the VP1(11^25) peptide
(1 Wg/well) and then reacted with ascitic £uids generated against each
of the peptide formulations. The antigen-antibody complex was de-
tected using an enzyme-labelled goat anti-mouse serum. Minimal pos-
itive ELISA (cut-o¡) values were calculated by adding 2 standard
deviations to the mean of tested reference negative ascites.
A competitive test was employed to assay the recognition of the
synthetic peptides by a human convalescent serum. The serum was
preincubated for 2 h at 37‡C with either 10 Wg of free peptide or
bovine serum albumin (BSA) in an equimolecular ratio per ml of
serum, and tested for HAV recognition in a sandwich ELISA. HAV
or FRhK-4 cell lysates were captured through MAb 33Z/37/39 and
detected by means of the convalescent serum. An enzyme-labelled
anti-human serum was employed to detect the antigen-antibody com-
plex. A statistically signi¢cant (b6 0.05; ANOVA test) decrease in
HAV recognition by the convalescent sera preincubated with HAV-
related peptides with regard to the same sera preincubated with BSA
was indicative of peptide recognition.
2.5. Virus recognition
HAV recognition by anti-peptide antibodies was tested by a com-
petitive ELISA, consisting of a preincubation of ascitic £uids with
intact HAV virus (5U105 MPNCU per ml of sample) for 2 h at
37‡C, before being added onto the immobilised peptides. Supernatants
from mock-infected FRhK-4 lysates were incubated with ascites and
used as negative controls. A statistically signi¢cant (b6 0.05; AN-
OVA test) decrease in peptide recognition by the anti-peptide ascites
preincubated with HAV with regard to the same ascites preincubated
with mock-infected cell lysates was indicative of virus recognition.
HAV recognition by antibodies generated using the virions as anti-
gen was evaluated by a sandwich ELISA. Viruses or mock-infected
cell lysates were captured by a convalescent serum, and detected by
the ascitic £uids. Minimal positive ELISA (cut-o¡) values were calcu-
lated by adding 2 standard deviations to the mean of optical densities
obtained with the mock-infected cell lysates.
2.6. Virus neutralisation
Ascitic £uids were assayed for their capacity to neutralise the in-
fectivity of HAV suspensions (3.5U105 MPNCU/ml) after a 3-h in-
cubation at 37‡C, as described elsewhere [11].
All experimental procedures were performed at least in triplicate.
3. Results and discussion
The HAV-VP3(110^121) sequence has recently been de-
scribed to contain a new continuous B-epitope of the virus
[12]. The e⁄cacy of liposomes as vehicles has been clearly
established for a great variety of antigens such as bacterial
toxoids [19,20], parasite proteins [21] and tumour antigens
[22]. It has been speculated that the attachment of peptides
to the surface of liposomes, instead of simple encapsulation,
could increase its immunogenicity [23]. In the present study,
neither the incorporation of the peptide as a lipopeptide, and
thus potentiating its interdigitation between the lipid bilayers,
nor its direct incorporation into the bilayer through a covalent
bond with phospholipids, enhanced its immunogenicity (Table
1). On the contrary, the anti-peptide response was of lower
magnitude, particularly with the palmitoyl-VP3 form, indicat-
ing a potential change on the B-epitope con¢guration since
the level of peptide incorporation into liposomes was higher
than the level obtained by entrapment of the unmodi¢ed pep-
tide. Since the super¢cial localisation of the liposome did not
increase the potential immunogenicity of the VP3 epitope,
entrapment into liposomes was the method of choice to deliv-
er VP3-modi¢ed sequences.
Combination of T- and B-cell epitopes in a synthetic pep-
tide, either by selecting sequences that naturally contain such
epitopes in proximity, or by arti¢cially coupling B- and T-cell
epitopes that lie apart in the natural sequence or even belong
to di¡erent proteins, has been suggested to be a useful ap-
proach to enhance the immunogenic properties of synthetic
peptides [24,25]. Two hundred and ¢fty Wg of the longer
VP3 peptides were administered entrapped into liposomes,
which represents 100 Wg of the B-epitope for the Anti-id
2F10-VP3 and VP3-Anti-id 2F10 peptides and 150 Wg for
the VP3(102^121) peptide. The VP3-Anti-id 2F10 peptide ex-
hibited a little enhancement of the humoral response against
the HAV-B-epitope with regard to the VP3(110^121) peptide,
since a lower dose of the B-cell epitope was given, and exerted
its e¡ect by increasing the anti-HAV titre, although in a much
lower proportion of animals (Table 2). On the contrary, the
Anti-id 2F10-VP3 peptide did not show any enhancement
e¡ect since lower anti-peptide titres were achieved than with
the VP3 sequence alone, and even no anti-HAV response was
obtained (Table 2). It has been described that chimeric pep-
tides composed of a T-cell epitope linked to the amino termi-
nus of a B-cell epitope induce the production of higher-a⁄nity
antibodies than does immunisation with peptides containing
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Fig. 1. Di¡erent forms of incorporation in liposomes of the
VP3(110^121) peptide.
Table 1
Immunogenicity of di¡erent liposome-VP3(110^121) preparations
Product Maximum anti-VP3 titre P/Ta
Liposome-entrapped VP3 1/10 000 3/6
Liposome-palmitoyl VP3 1/100 1/6
Liposome-covalent VP3 1/100 2/6
aAscites positive for peptide recognition/total ascites.
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the epitopes in the opposite orientation [26]. However, in our
case a worse response was evoked by the amino terminus
location of the HBV-derived T-cell epitope, which may be
due to the potentially di¡erent conformations adopted by
the HAV-B-cell epitope in each case. In similar studies per-
formed with a B-cell epitope of the FMDV, the position of
another HBV-derived T-cell epitope did not in£uence the re-
sponse [27]. The VP3(102^121) peptide showed an important
enhancement of the immunogenicity of the HAV-B-epitope in
terms of antibody titre, number of responding animals and
duration of this response, being of higher magnitude than
the one observed with the VP3-Anti-id 2F10 sequence. The
anti-HAV titres achieved with the VP3(102^121) peptide were
as high as 1:2000, which means 100 times higher than the
response obtained with the VP3(110^121) (Table 2). The pro-
portion of responding animals also increased (83% vs. 50%).
The recognition of both peptides VP3(110^121) and VP3(102^
121) by a human convalescent serum was similar, which im-
plies that the B-epitope contained in both sequences should be
identical. This recognition was evaluated as the percent inhib-
ition of human convalescent serum binding to HAV by the
di¡erent peptides in comparison to an equimolecular amount
of an unrelated protein as BSA. The inhibition achieved was
around 80% and 70% with the VP3(102^121) and the
VP3(110^121) peptides, respectively. Additionally, the
VP3(102^121) peptide was recognised by the anti-VP3(110^
121) at the same level that these antibodies recognised the
VP3(110^121) sequence and, vice versa, antibodies generated
with the VP3(102^121) peptide recognised both peptides
equally. All these results suggest the presence in this VP3
region of a natural T-epitope adjacent to the B-epitope.
This possibility is currently being investigated. Linkage of
B- and T-cell epitopes has been described in other viruses
[28] and suggests that their close proximity is a factor in
determining the e⁄ciency of the antibody response. The pu-
tative natural T-cell epitope of HAV is located at the amino
terminus of the B-cell epitope.
Synthetic polymers of selected amino acids such as MAP
have been used as carriers for di¡erent epitopes [29,30]. This
system presents the advantage of the possibility of incorporat-
ing di¡erent epitopes, or several copies of an epitope in the
same molecule. In the present work 250 Wg of the free MAP
polymers were assayed. The responses against both the VP3
and VP1 epitopes were very weak with any of the MAP con-
structs tested (Table 3). These lower responses in comparison
with the responses induced by the same sequences when ad-
ministered incorporated into liposomes are likely due to the
loss of the capacity of induction of cellular immunity by lip-
osomes [31]. However, the anti-VP1 response generated by the
MAP2ÿ2-VP3-VP1 was signi¢cantly higher than the anti-VP1
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Table 2
Immunogenicity enhancement of the VP3(110^121) peptide entrapped into liposomes by administration of larger peptides containing T-epitopes
Product Wg VP3(110^121) sequence Maximum anti-VP3 titre P/Ta Maximum anti-HAV titre P/Rb
Anti-id 2F10-VP3 100 1/1000 2/6 ^ 0/2
VP3-Anti-id 2F10 100 1/4000 5/6 1/100 2/5
VP3(102^121) 150 1/5000 5/6 1/2000 5/5
VP3(110^121) 250 1/10 000 3/6 1/20 3/3
aAscites positive for peptide recognition/total ascites.
bAscites positive for HAV recognition/ascites positive for peptide recognition.
Fig. 2. Peptides containing the VP3(110^121) sequence and a puta-
tive T-cell epitope, entrapped into liposomes. Bold amino acid se-
quences correspond to the B-cell epitope, non-bold sequences corre-
spond to the T-cell epitopes and underlined sequences correspond to
linker amino acids.
Fig. 3. MAP constructs containing the VP3(110^121) sequence and/
or the VP1(11^25) sequence.
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response generated with the inoculation of the MAP4-VP1
(Table 3). It should also be noted that a 500-Wg dose of the
MAP4-VP1 polymer [11] was required to induce a similar anti-
VP1 response as that of 250 Wg of the MAP2ÿ2-VP3-VP1
polymer, which contains only 125 Wg of the VP1 sequence.
These results also suggest the potential presence of a T-epi-
tope, which, however, would be incomplete, in the VP3 se-
quence, which acts on the VP1 sequence. In fact, this
VP3(110^121) sequence also aligns with the FMDV T-cell
epitope, with the exception of one residue from the amino
terminus of the FMDV sequence which is lost in the HAV
peptide [32]. The HAV-VP3(102^121) peptide contains the
complete sequence of the putative T-cell epitope. From a
structural point of view, the (110^121) sequence would ¢t
with the LD-sheet of the entire VP3 protein while the (102^
121) sequence would ¢t with the KA2-helix-LD-sheet of the
entire VP3 protein [32], and if this is also correct for the
peptides, the last conformation may contain an amphipathic
helical structure that may correlate with the localisation of a
T-cell determinant [33].
Since only the VP3(102^121) peptide induced an enhanced
response with regard to the VP3(110^121) peptide, compara-
tive studies between these two sequences and intact HAV
virions were performed, in terms of antigen dose, percent of
responding animals and duration of the response. The immu-
nogenic response induced by the VP3(110^121) and VP3(102^
121) sequences administered entrapped into liposomes in com-
parison with that of the intact HAV virion is depicted in
Table 4. Although the immune responses elicited by the
VP3(110^121) and VP3(102^121) sequences entrapped into
liposomes are of much lower magnitude than those of the
intact particles, since only one epitope is used which is not
the immunodominant site of the virion, it is relevant to point
out that a signi¢cance enhancement in the immune response,
in terms of titres and duration of response, is achieved simply
by increasing the length of the sequence. Future developments
include the synthesis of constructs containing the VP3(102^
121) and the VP1(11^25) sequences incorporated into lipo-
somes, with the aim of obtaining a synthetic vaccine formu-
lation containing more than one epitope.
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